Suppr超能文献

一种在非小细胞肺癌中具有强效活性的非交联铂-吖啶剂。

A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer.

作者信息

Ma Zhidong, Choudhury Jayati Roy, Wright Marcus W, Day Cynthia S, Saluta Gilda, Kucera Gregory L, Bierbach Ulrich

机构信息

Department of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, USA.

出版信息

J Med Chem. 2008 Dec 11;51(23):7574-80. doi: 10.1021/jm800900g.

Abstract

The cytotoxic complex, PtCl(Am)2(ACRAMTU)2 (1) ((Am)2 = ethane-1,2-diamine, en; ACRAMTU = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea), is a dual platinating/intercalating DNA binder that, unlike clinical platinum agents, does not induce DNA cross-links. Here, we demonstrate that substitution of the thiourea with an amidine group leads to greatly enhanced cytotoxicity in H460 non-small-cell lung cancer (NSCLC) in vitro and in vivo. Two complexes were synthesized: 4a (Am2 = en) and 4b (Am = NH3), in which N-[2-(acridin-9-ylamino)ethyl]-N-methylpropionamidine replaces ACRAMTU. Complex 4a proves to be a more efficient DNA binder than complex 1 and induces adducts in sequences not targeted by the prototype. Complexes 4a and 4b induce H460 cell kill with IC(50) values of 28 and 26 nM, respectively, and 4b slows tumor growth in a H460 mouse xenograft study by 40% when administered at a dose of 0.5 mg/kg. Compound 4b is the first non-cross-linking platinum agent endowed with promising activity in NSCLC.

摘要

细胞毒性复合物PtCl(Am)2(ACRAMTU)2 (1)((Am)2 = 乙二胺,en;ACRAMTU = 1-[2-(吖啶-9-基氨基)乙基]-1,3-二甲基硫脲)是一种双重铂化/嵌入DNA结合剂,与临床铂类药物不同,它不会诱导DNA交联。在此,我们证明用脒基取代硫脲会导致在体外和体内对H460非小细胞肺癌(NSCLC)的细胞毒性大大增强。合成了两种复合物:4a(Am2 = en)和4b(Am = NH3),其中N-[2-(吖啶-9-基氨基)乙基]-N-甲基丙脒取代了ACRAMTU。复合物4a被证明是比复合物1更有效的DNA结合剂,并在原型未靶向的序列中诱导加合物形成。复合物4a和4b分别以28和26 nM的IC(50)值诱导H460细胞死亡,并且在H460小鼠异种移植研究中,当以0.5 mg/kg的剂量给药时,4b使肿瘤生长减缓40%。化合物4b是第一种在NSCLC中具有有前景活性的非交联铂类药物。

相似文献

1
2
4
Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity.
J Med Chem. 2007 May 3;50(9):2259-63. doi: 10.1021/jm0614376. Epub 2007 Apr 5.
7
pH and thermo dual stimulus-responsive liposome nanoparticles for targeted delivery of platinum-acridine hybrid agent.
Life Sci. 2019 Jan 15;217:41-48. doi: 10.1016/j.lfs.2018.11.052. Epub 2018 Nov 24.
10
DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers.
Chemistry. 2012 Oct 8;18(41):12926-34. doi: 10.1002/chem.201202050. Epub 2012 Sep 17.

引用本文的文献

2
Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update.
RSC Med Chem. 2024 Apr 17;15(6):1877-1898. doi: 10.1039/d3md00632h. eCollection 2024 Jun 19.
3
Development of Prodrug-Payloads for Targeted Therapeutic Applications of Platinum-Acridine Anticancer Agents.
Bioconjug Chem. 2023 Oct 18;34(10):1873-1881. doi: 10.1021/acs.bioconjchem.3c00368. Epub 2023 Oct 9.
4
Platinum-Acridine Agents with High Activity in Cancers Expressing the Solute Carrier MATE1 ().
ACS Med Chem Lett. 2023 Jul 25;14(8):1122-1128. doi: 10.1021/acsmedchemlett.3c00266. eCollection 2023 Aug 10.
5
Tuning anticancer properties and DNA-binding of Pt(ii) complexes alteration of nitrogen softness/basicity of tridentate ligands.
RSC Adv. 2023 Mar 21;13(14):9333-9346. doi: 10.1039/d3ra00395g. eCollection 2023 Mar 20.
9
Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.
ChemMedChem. 2021 Jan 19;16(2):412-419. doi: 10.1002/cmdc.202000637. Epub 2020 Oct 22.
10
Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.
Angew Chem Int Ed Engl. 2020 Dec 1;59(49):21965-21970. doi: 10.1002/anie.202009983. Epub 2020 Sep 29.

本文引用的文献

1
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects.
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8902-7. doi: 10.1073/pnas.0803441105. Epub 2008 Jun 25.
2
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Lung Cancer. 2008 Mar;59(3):377-84. doi: 10.1016/j.lungcan.2007.08.025. Epub 2007 Oct 1.
3
The resurgence of platinum-based cancer chemotherapy.
Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12.
4
ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial.
J Clin Oncol. 2007 Jul 1;25(19):2648-9. doi: 10.1200/JCO.2007.11.3167.
5
Molecular predictors of chemotherapy response in non-small-cell lung cancer.
Expert Rev Anticancer Ther. 2007 Apr;7(4):545-9. doi: 10.1586/14737140.7.4.545.
6
Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity.
J Med Chem. 2007 May 3;50(9):2259-63. doi: 10.1021/jm0614376. Epub 2007 Apr 5.
7
Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
Oncologist. 2007 Mar;12(3):331-7. doi: 10.1634/theoncologist.12-3-331.
8
Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores.
Anticancer Agents Med Chem. 2007 Jan;7(1):125-38. doi: 10.2174/187152007779313991.
9
Molecular mechanisms of resistance and toxicity associated with platinating agents.
Cancer Treat Rev. 2007 Feb;33(1):9-23. doi: 10.1016/j.ctrv.2006.09.006. Epub 2006 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验